PDCD1 and neoplasm: By profiling the proteome of clinical samples from patients with advanced-stage melanoma undergoing either tumor-infiltrating lymphocyte (TIL)-based or anti-PD1 antibody immunotherapy, the authors discovered that compared to non-responders, responders are demarcated by higher oxidative phosphorylation and lipid metabolism.